2023-504571-25-00
进行中（未招募）
1 期
A Study Evaluating the Safety and Pharmacokinetics of Escalating Doses of Forimtamig in Participants With Relapsed or Refractory Multiple Myeloma
概览
- 阶段
- 1 期
- 干预措施
- 未指定
- 疾病 / 适应症
- 未指定
- 发起方
- F. Hoffmann-La Roche AG
- 入组人数
- 180
- 试验地点
- 13
- 状态
- 进行中（未招募）
- 最后更新
- 10个月前
概览
简要总结
暂无简介。
研究者
Trial Information System - TISL
Scientific
F. Hoffmann-La Roche AG
入排标准
入选标准
- 未提供
排除标准
- 未提供
结局指标
主要结局
未指定
研究点 (13)
Loading locations...
相似试验
进行中（未招募）
1 期
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of XmAb24306 in Combination with Cevostamab in Patients with Relapsed/Refractory Multiple Myeloma2023-505212-38-00Genentech Inc.43
进行中（未招募）
1 期
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7496353 in Combination with a Checkpoint Inhibitor with or without Standard-of-Care Chemotherapy in Patients with Locally Advanced or Metastatic Solid Tumors2022-502615-11-00Genentech Inc., Genentech Inc.35
已完成
1 期
Study to evaluate the pharmacokinetics, safety and tolerability of Secukinumab in patients with GCA or PMR2023-507667-19-00Novartis Pharma AG24
招募中
1 期
Study of safety, tolerability, pharmacokinetics and pharmacodynamics of MSD-001 in healthy participants2024-512939-67-00Mindstate Design Labs Inc.68
进行中（未招募）
1 期
A Study Evaluating the Safety, Pharmacokinetics, and Activity of GDC-9545 Alone or in Combination with Palbociclib and/or LHRH Agonist in Patients with Locally Advanced or Metastatic Estrogen Receptor−Positive Breast Cancer2023-506700-12-00Genentech Inc.45